Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.
We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58.3%) being woman. They have a mean age of 57.8 years and mean disease duration of 11.83 (SD 9.92) months. Our patients comprised of multi-ethnic groups with predominantly Chinese (83.3%), Sarawak natives (8.3%) and Malays (8.3%). They have a mean lag time to diagnosis of 3.67 (SD 4.27) months. Nine (75%) patients had dermatomyositis and 3(25%) had polymyositis. The common clinical manifestations found in our patients were proximal myopathy (100%), neck weakness (33.3%), dysphagia (33.3%) and interstitial lung disease (33.3%). For the nine patients with dermatomyositis, the most common dermatological manifestations were shawl sign (88.9%) and V sign (88.9%). Muscle enzymes were raised in 91.7% of patients. Electromyographies were carried out in four patients, and only one of our patients had muscle biopsy. Only 41.7% of our patients have positive ANA. The majority received prednisolone (100%) and hydroxychloroquine (58.3%). Malignancy occurred in five (three nasopharyngeal carcinomas, one sigmoid colon cancer and one lung cancer) out of the nine dermatomyositis patients but none in the polymyositis group. The mortality rate in our group was 4(33.3%) over the 4-year period. This study demonstrated the rarity of PM/DM in our centre with considerable lag time to diagnosis in our patients. Despite lack of muscle biopsy in our centre, our centre achieved appropriate diagnosis and management of PM/DM.
Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450 Kuching, Sarawak, East Malaysia. tehchenglay@yahoo.com
C L
CL
Teh
J S
JS
Wong
H H
HH
Soo
D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001706:Biopsy; D003430:Cross-Sectional Studies; D003882:Dermatomyositis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D004576:Electromyography; D005260:Female; D005500:Follow-Up Studies; D006769:Hospitals, General / Q000706:statistics & numerical data*; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008296:Malaysia; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology; D017285:Polymyositis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D011239:Prednisolone / Q000627:therapeutic use; D015995:Prevalence; D012189:Retrospective Studies; D013997:Time Factors
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine; D011239:Prednisolone
Br J Cancer. 2001 Jul 6;85(1):41-5
11437400
J Rheumatol. 1995 Jul;22(7):1300-3
7562762
Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):77-80
19499841
Rheum Dis Clin North Am. 2002 Nov;28(4):723-41
12510664
Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1298-301
7576478
N Engl J Med. 1975 Feb 13;292(7):344-7
1090839
J Rheumatol. 1990 Oct;17(10):1329-34
2254890
J Assoc Physicians India. 2002 Oct;50:1255-8
12568209
Semin Arthritis Rheum. 1996 Aug;26(1):447-58
8870112
Med J Malaysia. 1995 Mar;50(1):32-6
7752973
Ann Rheum Dis. 1993 Dec;52(12):857-61
8311535
Curr Opin Rheumatol. 2000 Nov;12(6):498-500
11092198
Ann Rheum Dis. 2000 Feb;59(2):141-2
10666171
Australas J Dermatol. 2004 Feb;45(1):77-8
14961918
Clin Rheumatol. 2006 Mar;25(2):234-9
16477398